Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. The study ...

A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high ...

A new study has uncovered an unexpected vulnerability in some of the deadliest cancers. Researchers at UCLA have identified a ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

Treatments targeting the androgen receptor have extended the lives of people with advanced prostate cancer. At first, prostate cancers need androgens like testosterone to survive, and blocking these ...

Prostate cancer is the second most common cancer for men in the United States (after skin cancer) and is the second leading cause of cancer deaths (after lung cancer). The American Cancer Society ...

Scientists have learned that prostate cancers can vary significantly among patients and that there are often differences within each patient's tumor. However, the study published Aug. 28 in Nature ...

Picking the right target and helping recruit a wider range of anti-tumor immune cells can help improve CAR T-cell therapy against advanced prostate cancer, according to new preclinical work from Fred ...

Prostate cancer is the fifth leading cause of death from cancer (after lung, liver, colorectum and stomach) across the world and the third most common cause of death from male specific cancers in ...

PSMA PET has become central to prostate cancer imaging as advanced disease incidence rises and prostate-specific membrane ...